脊柱肌肉缩的拯救生命的治疗方法:全球获取和可用性
Victor D Armengol1, Basil T Darras1, Ahmad A Abulaban1
1Department of Neurology (VDA, BR), Yale University School of Medicine, New Haven, CT; Department of Neurology (BTD), Boston Children's Hospital, MA; Department of Medicine (AAA), King Saud Bin Abdulaziz University for Health Sciences; Neuromuscular Integrated Practice Unit (AA), Neuroscience Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; Department of Pediatrics (NB), University of Zagreb Medical School, Croatia; Genetics and Genomic Medicine Division (TB-O), Sidra Medicine and Hamad Medical Corporation, Doha, Qatar; Department of Pediatrics (GB), Klinik Favoriten, Vienna, Austria; Department of Pediatrics (CC), Clínica Meds, Santiago, Chile; Department of Medical Genetics and Pediatrics (Y-HC), National Taiwan University Hospital, Taipei; Department of Neurology (MAF), Sydney Children's Hospital Network, New South Wales, Australia; Department of Paediatrics and Child Health (GK), College of Health Sciences, University of Zimbabwe, Harare; Department of Neurology (SK), Bombay Hospital, India; Department of Pediatrics (JM), University of Calgary Cumming School of Medicine, Alberta, Canada; John Walton Muscular Dystrophy Research Centre (CM-B), Newcastle University, Newcastle Upon Tyne, United Kingdom; Department of Child (DO), Adolescent, and Developmental Neurology, Children's Hospital, University Medical Centre Ljubljana, Slovenia; Department of Medical Genetics (GP), University of Calgary Cumming School of Medicine, Alberta, Canada; Neurometabolic Unit (FBP), University of Sao Paulo, Brazil; Department of Pediatrics (IPC), Hospital Universitari i Politècnic La Fe, Valencia, Spain; Child Neurology and ICU Department (SQ-R), Raymond Poincaré University Hospital (UVSQ), Garche, France; Institute of Medical Genetics (KS), Tokyo Women's Medical University, Japan; Department of Neurology (J-HS), Pusan National University Yangsan Hospital, South Korea; Neuromuscular Unit (JFV-C), Hospital Universitario y Politécnico la Fe, Valencia, Spain; Friedrich-Baur-Institute (MCW), Department of Neurology, Ludwig-Maximilians-University of Munich, Germany; Department of Paediatrics (JW), University of Colombo, Sri Lanka; Department of Pediatrics (HX), Peking University First Hospital, China; and Department of Neurology (RCG), University of Rochester Medical Center, NY.
脊椎肌肉缩 (SMA) 的新疗法改善了患者的治疗结果,但全球的治疗机会不平等. 新生儿查对全球早期诊断和公平护理至关重要.
科学领域:
- 神经学 神经学
- 遗传学 是一个遗传学.
- 公共卫生 公共卫生
背景情况:
- 脊椎肌肉缩 (SMA) 是一种进展性神经退行性疾病.
- 最近的进展包括基因替代和拼接修饰疗法.
- 这些治疗方法显著改善了SMA患者的生存率和生活质量.
研究的目的:
- 为了比较全球SMA治疗的可用性和实施情况.
- 确定获得护理和治疗障碍的差异.
主要方法:
- 质量研究调查了21个国家的医疗保健提供者.
- 评估新生儿查,药物可用性和治疗障碍.
主要成果:
- 全球范围内,努辛森是最可用的SMA疗法.
- 基因检测是广泛可用的,但新生儿查不是.
- 在许多地区,高昂的治疗费用是医疗保健的主要障碍.
结论:
- 在管理SMA方面存在重大的全球不平等.
- 扩大新生儿查对于改善SMA患者获得护理至关重要.
- 需要新的策略来解决遗传疾病临床护理方面的差异.
相关概念视频
Satellite Stem Cells and Muscular Dystrophy
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Skeletal Muscle Relaxants: Therapeutic Uses


